RT Journal Article
T1 Factors associated with the development of second primary tumours in head and neck cancer patients.
A1 Salcedo-Bellido, Inmaculada
A1 Requena, Pilar
A1 Mateos, Rocio
A1 Ortega-Rico, Carmen
A1 Olmedo-Requena, Rocio
A1 Lozano-Lorca, Macarena
A1 Arrebola, Juan Pedro
A1 Barrios-Rodriguez, Rocio
K1 head and neck cancer
K1 second primary tumours
AB The development of second primary tumours (SPTs) is one of the main causes of low survival in patients with head and neck cancer (HNC). The aim of this study was to review the evidence about factors associated with developing SPTs in patients with HNC. An updated systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines, and the search was performed in Pubmed and Scopus. Only original articles with a cohort or case-control design were included. Article quality was assessed with the Newcastle-Ottawa scale. Thirty-six and two case-control studies were included, with quality medium (n = 5) to high (n = 33). Tobacco showed a significant association with SPT development, with risks ranging from 1.41 (95%CI: 1.04-1.91) to 5.52 (95%CI: 2.91-10.49). Regarding alcohol, risks ranged from 1.46 (95%CI: 1.12-1.91) to 21.3 (95%CI: 2.9-156). Location of the index tumour in the hypopharynx/oropharynx, absence of human papillomavirus and presence of a premalignant lesion also increased the risk of SPTs. More controversy was found for sex, age and other clinical factors of the tumour. Toxic lifestyle habits and clinical factors were associated with the risk of SPTs in HNC patients. These findings may improve individualised prevention strategies in its follow-up.
PB Hindawi Limited
YR 2022
FD 2022-08-31
LK http://hdl.handle.net/10668/19945
UL http://hdl.handle.net/10668/19945
LA en
NO Salcedo-Bellido I, Requena P, Mateos R, Ortega-Rico C, Olmedo-Requena R, Lozano-Lorca M, et al. Factors associated with the development of second primary tumours in head and neck cancer patients. Eur J Cancer Care (Engl). 2022 Nov;31(6):e13699.
DS RISalud
RD Apr 11, 2025